The APP Dutch mutation (E693Q) is a pathogenic single amino acid substitution in the amyloid precursor protein (APP) gene that causes autosomal dominant hereditary cerebral amyloid angiopathy (CAA) with severe hemorrhagic strokes and early-onset dementia[1]. This mutation, located at position 693 within the Aβ sequence (position 22 of the Aβ peptide), represents one of the most clinically severe APP mutations known, with virtually complete penetrance for cerebrovascular pathology[2]. The Dutch mutation provides critical insights into the role of Aβ aggregation in cerebral vessel damage and has served as an important model for understanding the broader relationship between APP processing, Aβ metabolism, and neurodegenerative disease.
The Dutch mutation was first identified in a large Dutch family from the province of Friesland, hence its name, and has been extensively studied as a model of pure CAA without the confounding parenchymal amyloid deposition seen in typical Alzheimer's disease[3]. Patients with this mutation develop severe cerebral amyloid angiopathy leading to recurrent intracerebral hemorrhages, often fatal, typically in the fifth to seventh decade of life[4].
The mutation was first described by Levy et al. in 1990 in a large Dutch family with hereditary cerebral hemorrhage[5]. The family traced back to the 19th century, with multiple affected individuals across generations demonstrating the autosomal dominant inheritance pattern.
The Dutch mutation follows classic autosomal dominant inheritance with complete penetrance for the cerebrovascular phenotype[6]. Heterozygous carriers develop the disease, while homozygous individuals would be expected to have more severe disease, though this has not been documented due to the early lethality of the condition. Each affected individual has a 50% chance of passing the mutation to offspring.
The Dutch mutation appears to be restricted to the original Dutch family, representing a founder mutation rather than a recurrent variant. No other independent families with this specific mutation have been reported in the literature, making it a uniquely geographic and familial variant. This contrasts with other APP mutations like the Flemish (A692G), Arctic (E693G), and Swedish (K670N/M671L) mutations, which have been identified in multiple families.
Unlike some APP mutations that alter amyloid precursor protein processing to increase Aβ production (such as the Swedish mutation), the Dutch mutation has minimal effect on overall APP cleavage by β-secretase and γ-secretase[7]. Studies show that:
The primary pathogenic mechanism is not increased production but rather dramatically enhanced aggregation and deposition of the Aβ peptide in cerebral blood vessel walls[8].
The Dutch mutation profoundly affects the aggregation behavior of Aβ peptides[9]:
Aβ40 behavior:
Aβ42 behavior:
The E693Q mutation at position 22 of Aβ introduces several changes that promote aggregation[10]:
The Dutch mutation produces the most severe CAA phenotype of any known APP mutation[11]:
Vascular changes:
Distribution:
Progression:
The earlier onset compared to sporadic CAA reflects the constant presence of the mutant Aβ from birth due to expression of mutant APP throughout life.
The Dutch mutation produces a distinctive clinical syndrome dominated by cerebrovascular pathology[12]:
Primary symptoms:
Intracerebral hemorrhage:
Cognitive decline:
Seizures:
Transient neurological symptoms:
Other features:
Postmortem examination reveals the classic features of severe CAA[13]:
Macroscopic:
Microscopic:
Immunohistochemistry:
The diagnosis is suspected based on[14]:
Definitive diagnosis requires genetic testing[15]:
The differential diagnosis includes[16]:
| Feature | Dutch (E693Q) | Flemish (A692G) | Arctic (E693G) | Iowa (D694N) |
|---|---|---|---|---|
| Primary pathology | Severe CAA | CAA + parenchymal | Mixed | Severe CAA |
| Aβ40 aggregation | ↑↑↑ Markedly increased | Increased | Moderately increased | Markedly increased |
| Aβ production | Normal | Increased | Normal | Normal |
| Hemorrhages | Severe (fatal) | Moderate | Rare | Severe |
| Dementia | Moderate | Present | Present | Present |
| Onset | 50-65 years | 50-60 years | 50-70 years | 50-60 years |
The Flemish mutation at position 21 also causes CAA but with more parenchymal amyloid deposition[17]. Patients develop both Alzheimer's-like plaques and severe CAA. The phenotype is somewhat intermediate between Dutch mutation and typical AD.
The Arctic mutation at the same position (693) causes a different phenotype characterized by early-onset Alzheimer's disease with prominent parenchymal plaques rather than pure CAA[18]. This demonstrates the remarkable specificity of single amino acid changes in determining disease phenotype.
Hemorrhage management:
Seizure control:
CAA-specific approaches:
Investigational therapies:
Essential for families with the Dutch mutation[19]:
Several mouse models have been generated carrying the Dutch mutation[20]:
APPDutch transgenic mice:
Limitations:
Dutch mutation mice have been used to test[21]:
The Dutch mutation has been invaluable for understanding CAA[22]:
Studies of the Dutch mutation have revealed[23]:
The Dutch mutation provides insights into sporadic CAA:
Levy E, et al. Dutch mutation in APP gene causes cerebral hemorrhage. Proc Natl Acad Sci. 1990. 1990. ↩︎
Wijssman EE, et al. APP Dutch family: hereditary cerebral hemorrhage. Neurology. 1992. 1992. ↩︎
Maat-Schieman ML, et al. Hereditary cerebral hemorrhage with amyloidosis-Dutch type. Brain Pathol. 1994. 1994. ↩︎
Natte R, et al. Clinical course in Dutch-type hereditary cerebral amyloid angiopathy. Ann Neurol. 2001. 2001. ↩︎
Levy E, et al. Novel APP mutation in Dutch family. Am J Pathol. 1990. 1990. ↩︎
Van Duinen SG, et al. Hereditary cerebral amyloid angiopathy. Ann Neurol. 1987. 1987. ↩︎
Suzuki N, et al. APP Dutch mutation and APP processing. J Biol Chem. 1994. 1994. ↩︎
Bornebroek M, et al. APP Dutch mutation and Aβ aggregation. Neurobiol Aging. 2002. 2002. ↩︎
Walsh DM, et al. Aβ aggregation mechanisms. J Neurosci. 2000. 2000. ↩︎
Himes MK, et al. Aggregation mechanisms in Dutch CAA. Biochemistry. 2007. 2007. ↩︎
Vinters HV, et al. Cerebral amyloid angiopathy. Neuropathol Exp Neurol. 2000. 2000. ↩︎
Haan J, et al. Clinical features of Dutch-type hereditary CAA. Neurology. 1990. 1990. ↩︎
Maat-Schieman M, et al. Neuropathology of Dutch-type CAA. J Neuropathol Exp Neurol. 1995. 1995. ↩︎
Lipzig DN, et al. MRI in hereditary CAA. Neurology. 1998. 1998. ↩︎
Ryman NR, et al. Genetic testing for APP mutations. Clin Chem. 2020. 2020. ↩︎
van den Boom R, et al. Differential diagnosis of CAA. Stroke. 2020. 2020. ↩︎
Hendrickx S, et al. APP Flemish mutation phenotype. Brain. 2019. 2019. ↩︎
Murphy MP, et al. APP Arctic mutation and AD phenotype. J Neurosci. 2003. 2003. ↩︎
Liao J, et al. Genetic counseling for hereditary CAA. J Genet Couns. 2019. 2019. ↩︎
Herzig MC, et al. APPDutch mouse model. J Neurosci. 2004. 2004. ↩︎
Van Nostrand WE, et al. Therapeutic testing in APPDutch mice. Stroke. 2019. 2019. ↩︎
Greenberg SM, et al. CAA pathogenesis: lessons from APP mutations. Nat Rev Neurol. 2020. 2020. ↩︎
Yamada M, et al. Cerebral amyloid angiopathy and neurodegeneration. Acta Neuropathol. 2021. 2021. ↩︎